Irritable bowel syndrome: Saccharomyces improves pain and stool consistency

  • Gayathri R & al.
  • Int J Colorectal Dis
  • 5 Dec 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • As an adjunct for the treatment of irritable bowel syndrome (IBS), Saccharomyces cerevisiae CNCM I-3856 may be useful.

Why this matters

  • Derived from baker’s yeast, S cerevisiae CNCM I-3856 has documented prokinetic, antiinflammatory, and analgesic properties.

Key results

  • Abdominal pain score reduction at 8 weeks vs baseline, Saccharomyces vs placebo groups: 1.708±0.92 vs 0.45±0.697; P<.001.>
  • Similar trends in subgroups with mixed and with diarrhoea- and constipation-predominant IBS.
  • Stool consistency improvements at 8 weeks vs baseline:
    • Diarrhoea-predominant IBS (baseline Bristol score about 6 in both groups): −1.728±0.859 vs −0.483±0.688 (P=.001).
    • Constipation-predominant IBS (baseline Bristol score about 2 in both groups): +1.97±0.994 vs +0.80±1.135 (P=.015).
  • Study design

    • Single-centre 10-week prospective randomised controlled study of 100 adults newly diagnosed with IBS.
    • Along with 2 weeks of standard therapy, participants were randomly assigned to add S cerevisiae CNCM I-3856 (2 billion CFU twice daily) vs placebo for 8 weeks.
    • Outcomes: changes in abdominal pain (measured on 0-7 Likert scale; 7 is severe pain), stool consistency (Bristol stool scale; 1 is constipated, 7 diarrhoea).
    • Funding: None disclosed.

    Limitations

    • Short duration.